Glucagon‐like peptide 1 receptor agonist for peripheral artery disease: Is it time to proceed?
DG received a consultancy fee from Eli Lilly and has given lectures from Eli Lilly, Sanofi, Novartis, Astrazeneca and Novo Nordisk. MIM has given lectures for Novo Nordisk, Eli Lilly, and Sanofi. KE received a consultancy fee from Eli Lilly and has given lectures from Eli Lilly, Sanofi, Novo Nordisk, Roche, Bayer and Lifescan. All other authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work. The peer review history for this article is available at https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/dom.70246.
Authors
- Giuseppe Bellastella (ORCID: https://orcid.org/0000-0002-4748-321X)
- Maria Ida Maiorino (ORCID: https://orcid.org/0000-0003-4659-7546)
- Katherine Esposito (ORCID: https://orcid.org/0000-0002-3652-5154)
- Paola Caruso (ORCID: https://orcid.org/0000-0002-4756-2022)
- Dario Giugliano (ORCID: https://orcid.org/0000-0002-9377-873X)
Institutions
- University of Campania "Luigi Vanvitelli" (IT)
- University of Campania "Luigi Vanvitelli" (IT)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-11-03
- DOI
- https://doi.org/10.1111/dom.70246
- Citations
- 1
- Primary Topic
- Peripheral Artery Disease Management
- Type
- article
- Field-Weighted Citation Impact
- 2.01